Aspergillus species, a common saprophytic mold, seldom acts as a pathogen in immunocompetent hosts, and primary cutaneous involvement is even less. Herein, we report a patient of primary cutaneous aspergillosis harboring CARD9 mutations. The 45-year-old patient presented with a 37-year history of skin lesions on the face. The lesion was a soy-sized rash on his left eyelid at the age of 8, which slowly enlarged and progressed during the past 3 years. Physical examination revealed erythematous plaques with clear border on his face and nose. Direct microscopic examination showed slender, septate, branched hyphae. A biopsy specimen revealed mixed inflammatory infiltrations with septate hyphae noted in multinuclear giant cells. From tissue cultures, Aspergillus fumigatus was isolated and identified. The patient denied any immunosuppressive conditions, and results of routine laboratory examinations were generally normal. A CT scan excluded pulmonary aspergillosis. Therefore, the diagnosis of primary cutaneous aspergillosis was made on the basis of the above findings. The patient responds well to oral itraconazole and is still under treatment. To study the reason for the prolonged infection and identify the genetic background in this seemingly immunocompetent patient, we screened mutations in several related genes. Sanger sequencing of CARD9 showed that the patient harbored a homozygous frame shift mutation in exon 6 (c.819_820insG, p.D274fsX60), leading to premature termination codons. His son was asymptomatic and heterozygous carrier of the same mutation. CARD9, mainly expressed in myeloid cells, is a key adaptor in the downstream signaling of several C-type lectin receptors, and mediates anti-fungal immunity by forming a complex with BCL10 and MALT1. This is, to our knowledge, the first report that linked cutaneous aspergillosis to CARD9 mutations. This work enriches both the phenotypic spectrum of CARD9 deficiencies and the genetic background of primary cutaneous aspergillosis.
Ex vivo skin culture is used as a proxy for understanding cutaneous biology. A potential confounding factor of this method is culture-induced expression of cytokines and chemokines. These studies were designed to investigate mechanism(s) of skin culture-induced cytokine and chemokine expression. Time course studies of ex vivo-cultured mouse tail skin were performed, and transcript for Il1a, Il6, Tnf, Tslp, Csf2 and Cxcl1 were measured by quantitative PCR. Compared to freshly isolated skin, Il6, Csf2, and Cxcl1 were significantly increased within 4 hours of culture; in contrast, Il1a, Tnf and Tslp increased later (e.g. 24 hours). Studies with a small molecule inhibitor suggested a role for TLR3 in culture-induced cytokine and chemokine expression; however experiments with skin from TLR3 knockout mice and separate experiments with an RNase cocktail added to cultures did not support this conclusion. In addition, TLR9 blockade with inhibitory oligodeoxynucleotides 2088 or INH-18 did not affect transcript levels. To investigate a role for other TLRs and IL-1 family signaling, studies were performed with skin from Myd88 deficient mice. Relative to wild type, Il1a, Tnf, Csf2 and Cxcl1 were reduced in Myd88 deficient skin; however, all cytokine and chemokine transcripts examined increased during culture. These data demonstrate TLR3 and TLR9 are dispensable and that Myd88-dependent signaling amplifies but does not initiate culture-induced cytokine and chemokine expression in mouse skin.
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Ablation of macrophages from hypodermal adventitia disrupts the collagen network resulting in hyperelastic skin B Voisin 1 , T Doebel 1 , M Kelly 2 , T Kobayashi 1 , D Kim 1 , C Yan 3 , Y Hu 3 , M Kelley 2 and K Nagao 1 1 NIAMS/NIH, Bethesda, MD, 2 Laboratory of Cochlear Development, NIDCD, NIH, Bethesda, MD and 3 National Institutes of Health, Rockville, MD Skin is a complex multi-layered organ in which structure and cellular composition of each layer reflect its functional specialization. Both immune and stromal cells in superficial layers of the skin, epidermis and dermis, have been extensively studied. However, deeper layers of the skin -the hypodermis -remain largely unexplored. We used single-cell RNA-sequencing (scRNA-seq) to establish comparative maps of the cellular landscape of hypodermis and dermis. Ablation of myeloid subsets in Ccr2-KO mice and colony stimulating factor 1 (Csf1)op/wt mice resulted in prominent changes in extracellular matrix (ECM)-associated genes in hypodermal fibroblasts at the single cell level. Using our scRNA-seq data we identified fibroblasts and endothelial cells as major sources of CSF1 in both dermis and hypodermis and found that a Tie2-Cre driver line would enable layer-specific deletion of CSF1 in the hypodermis. Accordingly, analysis of Tie2-Cre x Csf1-floxed mice revealed a mild effect on dermal macrophages while macrophages from the hypodermal adventitia were eradicated. The hypodermal adventitia connects the skin to the underlying skeletal muscles and mediates skin flexibility. Notably, Tie2-Cre x Csf1-floxed mice exhibited skin hyperelasticity. Immunofluorescence microscopy revealed altered type I, III, and V collagen networks and special stains and transmission electron microscopy further revealed that large collagen fibers were insufficiently formed in Tie2-Cre x Csf1-floxed mouse adventitia. Altogether, our data show that steady-state hypodermal macrophages regulate the integrity of the hypodermal ECM. Loss of macrophages resulted in altered collagen networks in the hypodermal adventitia that manifested as skin hyperelasticity, a feature observed in genetic connective tissue disorders or aged skin.
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Role of IL-36 in acute generalized exanthematous pustulosis B Meier 1 , M Mellett 1 , L Feldmeyer 2 , D Jankovic 3 , A Navarini 4 , E Contassot 5 and LE French 5 1 Dermatology, University of Zürich, Zurich, Switzerland, 2 Department of Dermatology, University Hospital Bern, Bern, Switzerland, 3 Department of Dermatology, University Hospital Zurich, Zurich, Switzerland, 4 University Hospital Zurich (USZ), Zurich, Switzerland and 5 Dermatology, USZ, Zurich, Switzerland Acute Generalized Exanthematous Pustulosis (AGEP) is a severe cutaneous adverse drug reaction characterized by an acute onset of sterile pustules on an erythematous background, fever and peripheral blood neutrophilia. Even though it is hypothesized that the massive neutrophilic infiltration seen in skin lesions is mediated by memory T cells via the production of IL-8, little is known about the early pathophysiology of AGEP. In our study, we could identify IL-36 as a possible key player in AGEP pathogenesis. Using gene expression profiling, quantitative Real Time PCR and immunohistochemistry, we found elevated levels of IL-36 in the skin of AGEP patients when compared to maculo-papular rash (MPR), a milder, common form of drug-induced skin reaction. Notably, the majority of IL-36-expressing epidermal cells was localized close to the pustules. Using immunofluorescence co-labeling, we could identify keratinocytes and macrophages and, to a lower extent, T cells as IL-36 expressing cells in AGEP lesional skin. Moreover, high levels of IL-36 could be found in the peripheral blood of AGEP patients. Collectively, our data suggest that IL-36 could be an important cytokine in the pathogenesis of AGEP. The study of IL-36 and its effects on immune and nonimmune cells of the skin cells may help to further understand the aberrant immune reactions occurring in these patients and possibly identify novel therapeutic targets.
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Non-clinical and human pharmacology of the potent and selective topical RARg agonist trifarotene J Aubert 1 , B Bertino 1 , S Blanchét-Rethore 1 , I Carlavan 1 , S Deret 2 , B Dréno 3 , A Luzy 1 , C Mounier 1 , J Pascau 2 , I Pelisson 1 , T Portal 4 , M Rivier 1 , P Rosso 1 , E Thoreau 5 , E Vial 2 and JJ Voegel 1 1 Galderma R&D, Biot, Provence-Alpes-Cote d'Azur, France, 2 Nestlé Skin Health, Galderma R&D, Biot, Provence-Alpes-Cote d'Azur, France, 3 CHU Nantes, CIC 1413, CRCINA, University Nantes, Nantes, Pays de la Loire, France, 4 Galderma SA, Lausanne, Vaud, Switzerland and 5 Nestlé Skin Health, Biot, Provence-Alpes-Cote d'Azur, France First-and third-generation retinoids even though efficacious in acne, lack full selectivity for RARg expressed in the epidermis and infundibulum. We describe the in vitro metabolism and the pharmacology of the novel retinoid trifarotene. Trifarotene is a selective RARg agonist with >20-fold selectivity over RARa and RARb. Trifarotene is active and stable in keratinocytes but rapidly metabolized by human hepatic microsomes, predicting improved safety. In vivo, trifarotene 0.01% applied topically is highly comedolytic and has antiinflammatory and antipigmenting properties. Gene expression studies indicated potent activation of known retinoid-modulated processes (epidermal differentiation, proliferation, stress response, RA metabolism) and novel pathways (proteolysis, transport/skin hydration, cell adhesion) in ex vivo and in vivo models, as well as in human skin after four weeks of topical application of trifarotene 0.005% cream. Based on its RARg selectivity, rapid degradation in human hepatic microsomes and pharmacological properties including potent modulation of epidermal processes, topical treatment with trifarotene could result in good efficacy and may present a favorable safety profile in acne and ichthyotic disorders.
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Structure-based design of Trifarotene, a potent and selective RAR agonist for the treatment of acne E Thoreau 1 , J Arlabosse 1 , C Bouix-peter 2 , S Chambon 1 , L Chantalat 3 , S Daver 1 , L Dumais 1 , G Duvert 1 , A Feret 1 , G Ouvry 4 , J Pascau 4 , C Raffin 1 , N Rodeville 5 , C Soulet 1 , S Tabet 1 , S Talano 1 and T Portal 6 1 Nestlé Skin Health, Biot, France, 2 Galderma R&D, Biot, France, 3 Nestlé Skin Health, New York, NY, 4 Nestlé Skin Health, Galderma R&D, Biot, France, 5 Virbac, Carros, France and 6 Galderma SA, Lausanne, Switzerland Retinoids have a dominant role in topical acne therapy and to date, only RARb and RARg dual agonists have reached the market. Given the tissue distribution of RAR isoforms, it was hypothesized that developing RARg eselective agonists could yield a new generation of topical acne treatments that would increase safety margins while maintaining the robust efficacy of previous drugs. Structural knowledge derived from the X-Ray structure of known geselective CD437, revealed an unprecedented and isotype specific pocket in the RARg ligand binding domain and enabled the optimization of a novel triaryl series of agonists which ultimately led to the discovery of Trifarotene.
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